WA
LGND icon

WPG Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

WPG Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.2K Hold
11
– – ﹤0.01% 1059
2025
Q4 		$2.08K Hold
11
– – ﹤0.01% 1118
2025
Q3 		$1.95K Hold
11
– – ﹤0.01% 1145
2025
Q2 		$1.25K Sell
11
-4
-27% -$428 ﹤0.01% 1220
2025
Q1 		$1.58K Hold
15
– – ﹤0.01% 1173
2024
Q4 		$1.61K Buy
+15
New +$1.7K ﹤0.01% 1125

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

WPG Advisers's LGND Position: Q1 2026 in Review

WPG Advisers held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 11 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

WPG Advisers first reported a position in LGND in Q4 2024 and has held it in 6 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • WPG Advisers held 11 shares of Ligand Pharmaceuticals worth $2.2K as of Q1 2026.
  • WPG Advisers left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of WPG Advisers's portfolio in Q1 2026, its #1059 holding.
  • WPG Advisers first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on WPG Advisers's 13F filing for Q1 2026, filed 30 Apr 2026.